Sino-US Laekna (HKG: 2105) has announced that its clinical trial application for LAE102, an antibody targeting adult obesity and metabolic disorders, has been accepted for review by the Center for Drug Evaluation (CDE).
LAE102 is a potent and selective monoclonal antibody against ActRIIA, known for its regulatory roles in tumor growth, immune activation, muscle regeneration, and hematopoietic development. In preclinical studies, LAE102 demonstrated the ability to increase skeletal muscle mass while reducing white fat. When combined with GLP-1 receptor agonists, LAE102 not only enhances fat reduction but also significantly mitigates muscle loss associated with these agonists, positioning it as a promising candidate for weight management that preserves muscle mass. Notably, LAE102 received clinical approval in the U.S. in May of the previous year for the treatment of non-small cell lung cancer.- Flcube.com
